Companies › Immunocore
4 active drug programs in 17 registered trials: 7 Phase 2, 6 Phase 1, 4 Phase 3; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Brenetafusp (IMC-F106C) Immune-mobilizing monoclonal T cell receptor (ImmTAC) targeting PRAME-positive cancer cell | PRAME | Phase 3 | Advanced Melanoma; Select Advanced Solid Tumors | Oct 2027 |
| Tebentafusp Melanocyte protein PMEL binding agent | PMEL | Phase 3 | Advanced Melanoma; Uveal Melanoma; Melanoma (Skin); Locally Advanced Unresectable Uveal Melanoma … | Mar 2028 |
| IMC-R117C PIWIL1 × CD3 bispecific ImmTAC protein | PIWIL1, CD3E | Phase 1 | Cancer | Nov 2026 |
| IMC-P115C Half-life extended (HLE) ImmTAC targeting PRAME; engages T cells to recognize PRAME-presen | PRAME | Phase 1 | PRAME Positive | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06840119 | IMC-R117C | Phase 1 | Cancer | Oncology | Nov 2026 |
| NCT05315258 | Tebentafusp | Phase 2 | Melanoma (Skin) | Oncology | Dec 2026 |
| NCT06414590 | Tebentafusp | Phase 2 | Locally Advanced Unresectable Uveal Melanoma | Oncology | Aug 2027 |
| NCT07063875 | Tebentafusp | Phase 1 | Uveal Melanoma | Oncology | Sep 2027 |
| NCT07156136 | IMC-P115C | Phase 1 | PRAME Positive | Oncology | Sep 2027 |
| NCT06112314 | Brenetafusp (IMC-F106C) | Phase 3 | Advanced Melanoma | Oncology | Oct 2027 |
| NCT07203391 | Tebentafusp | Phase 1 | Uveal Melanoma, Metastatic | Oncology | Dec 2027 |
| NCT04262466 | Brenetafusp (IMC-F106C) | Phase 1 | Select Advanced Solid Tumors | Oncology | Dec 2027 |
| NCT07057596 | Tebentafusp | Phase 2 | Mestastatic Uveal Melanoma | Oncology | Dec 2027 |
| NCT06627244 | Tebentafusp | Phase 2 | Metastatic Uveal Melanoma | Oncology | Feb 2028 |
| NCT05549297 | Tebentafusp | Phase 3 | Advanced Melanoma | Oncology | Mar 2028 |
| NCT05549297 | Tebentafusp | Phase 3 | Advanced Melanoma | Oncology | Mar 2028 |
| NCT06070012 | Tebentafusp | Phase 2 | Uveal Melanoma | Oncology | Sep 2028 |
| NCT06942442 | Tebentafusp | Phase 2 | HLA-A*0201 Positive Cells Present | Oncology | Oct 2030 |
| NCT06626516 | Tebentafusp | Phase 1 | Metastatic Uveal Melanoma | Oncology | Oct 2030 |
| NCT07276386 | Tebentafusp | Phase 2 | Metastatic Uveal Melanoma | Oncology | Dec 2030 |
| NCT06246149 | Tebentafusp | Phase 3 | Uveal Melanoma | Oncology | Nov 2032 |
Cash and short-term investments of $901m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Johnson & Johnson (Janssen) Regeneron Pharmaceuticals Amgen Roche AstraZeneca Neowise Biotechnology PDC*line Pharma SAS Immatics US Tiziana Life Sciences Sanofi
Genmab Exelixis Sellas Life Sciences Group Immatics US Erasca
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.